NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

不得在美国或美国传播或分发给美国新闻网服务

HERZLIYA, Israel and CALGARY, Alberta, Oct. 12, 2023 /PRNewswire/ -- Innocan Pharma Corporation (the 'Company') (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed the first of two tranches (the 'First Tranche') of its previously announced private placement offering (the 'Offering') of units of the Company (the 'Units'), pursuant to which the Company issued 1,420,200 Units at a price of $0.30 per Unit (the 'Offering Price') for aggregate gross proceeds of $426,060.

以色列HERZLIYA和艾伯塔省卡尔加里，2023年10月12日/PRNewswire/--Innocan Pharma Corporation（“公司”）（CSE:INNO）（FSE:IP4）（OTCQB:INNPF）很高兴地宣布它已关闭公司单位先前宣布的私人配售（'提供'）单位（'单位'）的两个部分中的第一部分（'第一部分'），根据该公司以每单位0.30美元的价格（“发行价格”）发行1420200单位，总收益总额为426060美元。

The Company expects to complete a second and final tranche of the Offering in the following week. .

该公司预计将在下周完成第二批也是最后一批产品。 .

The Offering is led by Research Capital Corporation as sole agent and sole bookrunner (the 'Agent').

该产品由Research Capital Corporation作为独家代理和独家图书管理员（“代理”）领导。

Each Unit is comprised of one common share of the Company (a 'Common Share') and one purchase warrant of the Company (a 'Warrant'). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of $0.36 for a period of 36 months from the closing of the First Tranche..

每个单位由本公司一股普通股（“普通股”）和本公司一份购买权证（“认股权证”）组成。每份认股权证应赋予持有人自第一批完成后36个月内以0.36元行使价购买一股普通股的权利。。

The Company intends to use the net proceeds from the Offering to fund the Company's pre-investigational new drug meeting with the United States Food and Drug Administration (the 'FDA') regarding the human application of the Company's products (the 'Pre-IND Meeting'); the investigational new animal drug meeting with the FDA regarding the veterinary application of the Company's products; and (iii) for the expansion of the Company's derma-cosmetic product distribution..

本公司打算利用本次发行的净收益为本公司与美国食品和药物管理局（'FDA'）就人类应用本公司产品进行的研究前新药会议（'pre-IND会议'）；与FDA就本公司产品的兽医应用召开的研究性新动物药物会议；（iii）扩大公司的皮肤化妆品分销。。

The Units issued under the First Tranche were offered to purchasers pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions ('NI 45-106'). The Units are not subject to resale restrictions pursuant to applicable Canadian securities laws. The Broker Warrants (as defined below) are subject to a statutory four-month hold period pursuant to applicable Canadian securities laws..

根据国家文书45-106第5A部分列出的发行人豁免-承销说明书豁免（'NI 45-106'），根据第一批发行的单位已提供给购买者。根据适用的加拿大证券法，这些单位不受转售限制。根据适用的加拿大证券法，经纪人认股权证（定义如下）受法定四个月持有期限的约束。。

In connection with the First Tranche, the Agent received an aggregate cash fee equal to $34,084.80. In addition, the Company issued to the Agent 113,616 non-transferable broker warrants (the 'Broker Warrants'). Each Broker Warrant entitles the holder thereof to purchase one Unit at an exercise price equal to the Offering Price for a period of 36 months following the closing date of the First Tranche..

就第一批而言，代理人收到的现金总额等于34084.80美元。此外，本公司向代理人＃113616不可转让经纪人认股权证（“经纪人认股权证”）。每个经纪人认股权证均赋予持有人在第一批截止日期后36个月内以等于发行价格的行使价格购买一个单位。。

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the '1933 Act') or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S.

本新闻稿不构成出售或征求购买报价的报价，也不构成在此类报价，征求或销售将非法的任何辖区内销售任何证券，包括任何证券在美利坚合众国。本文所述的证券尚未且不会根据1933年“美国证券法”（经修订的“1933年法案”）或任何州证券法注册，并且不得在美国或美国境内提供或销售，或为了美国的利益或利益。

Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available..

（根据1933年法案第S条的定义），除非根据1933年法案和适用的州证券法进行注册，或免除此类注册要求。。

Corporate Update

公司更新

The Company wishes to express its strong support of the State of Israel. Our heart goes out to all of the families that have been affected by the events of the past few days. We send strength to our soldiers, families and loved ones in these terrible times.

该公司希望表达对以色列国家的大力支持。我们的心走向所有受过去几天事件影响的家庭。在这些可怕的时期，我们为士兵，家人和亲人发力。

Despite the horrific situation in Israel, the Company continues to be full operational and active. All of our staff continue to work remotely while adhering to safety precautions and instructions from local authorities. We wish to thank all of our investors and partners for their continuing warm support..

尽管以色列情况可怕，但该公司仍在继续全面运营和活跃。我们所有的工作人员在遵守地方当局的安全预防措施和指示的同时继续远程工作。我们要感谢我们所有的投资者和合作伙伴的持续热情支持。。

We will continue with our growth and innovation, focusing on completing our preparation for the Pre-IND Meeting and the expansion of the Company's derma-cosmetic product distribution.

我们将继续发展和创新，重点是完成IND前会议的准备工作，并扩大公司的皮肤化妆品分销。

About Innocan

关于Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients' quality of life.

Innocan是一家制药技术公司，分为两大类：制药和消费者健康。在制药领域，Innocan专注于开发创新的药物输送平台-技术包括大麻素科学，治疗各种疾病以改善患者的生活质量。

This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management.

该部分涉及两种药物递送技术：（i）装载LPT CBD的脂质体平台，促进精确给药和CBD向血流中的延长和控制释放。LPT交付平台研究正处于两个适应症的临床前试验阶段：癫痫和疼痛管理。

(ii) CLX CBD-loaded exosomes platform that may hold the potential to provide a highly synergistic effect of regenerating and anti- inflammatory properties targeting the Central Nervous System (CNS). In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle.

（ii）载有CLX CBD的外泌体平台，其可能具有提供针对中枢神经系统（CNS）的再生和抗炎特性的高度协同效应的潜力。在消费者健康领域，Innocan开发并销售广泛的创新和高性能自我保健产品组合，以促进更健康的生活方式。

Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/ .

根据这一细分市场，Innocan以BI-Sky Global Ltd.的名义建立了合资企业，专注于开发先进的有针对性的在线销售。https://innocanpharma.com/ .

For further information, please contact:

有关详细信息，请联系：

Iris Bincovich, CEO15162104025++972-54-3012842+442037699377[email protected]

Iris Bincovich，CEO15162104025++972-54-3012842+442037699377[电子邮件保护]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

加拿大证券交易所及其监管服务提供商均未对此版本的充分性或准确性进行审核或承担责任。

Disclaimer for Forward-Looking Information

免责声明前瞻性信息

This news release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts are forward-looking statements. Such forward-looking statements and forward-looking information specifically include, but are not limited to, statements that relate to the completion of a second tranche of the Offering and the timing and pricing in respect thereof; the use of proceeds of the Offering; and timely receipt of all necessary approvals, including any requisite approval of the Canadian Securities Exchange..

本新闻稿包括某些声明和信息，这些声明和信息构成适用的加拿大证券法含义内的前瞻性信息。除历史事实陈述外，本新闻稿中的所有陈述均为前瞻性陈述。此类前瞻性陈述和前瞻性信息具体包括但不限于与完成第二部分产品有关的陈述及其时间和定价；产品收益的使用；并及时收到所有必要的批准，包括加拿大证券交易所的任何必要批准。。

Statements contained in this release that are not historical facts are forward-looking statements that involve various risks and uncertainty affecting the business of the Company. Such statements can generally, but not always, be identified by words such as 'expects', 'plans', 'anticipates', 'intends', 'estimates', 'forecasts', 'schedules', 'prepares', 'potential' and similar expressions, or that events or conditions 'will', 'would', 'may', 'could' or 'should' occur.

本版本中包含的非历史事实的陈述是前瞻性陈述，涉及影响公司业务的各种风险和不确定性。这样的陈述通常但不总是可以用“期望”，“计划”，“预期”，“意图”，“估计”，“预测”，“时间表”，“准备”，“潜力”等词语来识别，或者事件或条件“将会”，“可能”，“可能”或“应该”发生。

All statements that describe the Company's plans relating to operations and potential strategic opportunities are forward-looking statements under applicable securities laws. These statements address future events and conditions and are reliant on assumptions made by the Company's management, and so involve inherent risks and uncertainties, as disclosed in the Company's periodic filings with Canadian securities regulators.

所有描述公司与运营和潜在战略机会有关的计划的陈述都是适用证券法下的前瞻性陈述。这些陈述涉及未来的事件和条件，并依赖于公司管理层的假设，因此涉及公司与加拿大证券监管机构定期提交的文件中披露的固有风险和不确定性。

As a result of these risks and uncertainties, and the assumptions underlying the forward-looking information, actual results could materially differ from those currently projected, and there is no representation by the Company that the actual results realized in the future will be the same in whole or in part as those presented herein.

由于这些风险和不确定性以及前瞻性信息所依据的假设，实际结果可能与目前预计的结果大不相同，公司没有表示未来实现的实际结果将是相同的全部或部分如本文所述。

The Company disclaims any intent or obligation to update forward-looking statements or information except as required by law. Readers are referred to the additional information regarding the Company's business contained in the Company's reports filed with the securities regulatory authorities in Canada.

除法律要求外，本公司不承担更新前瞻性声明或信息的任何意图或义务。读者可以参考向加拿大证券监管机构提交的公司报告中包含的有关公司业务的其他信息。

Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that could cause actions, events or resul.

尽管公司试图找出可能导致实际行动，事件或结果与前瞻性陈述中描述的实质性差异的重要因素，但可能还有其他因素可能导致行动，事件或结果。

The Company provides no assurance that forward-looking statements and information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward-looking statements or information.

本公司不保证前瞻性陈述和信息将被证明是准确的，因为实际结果和未来事件可能与此类陈述或信息中预期的实质性差异。因此，读者不应过分依赖前瞻性陈述或信息。

The Company does not undertake to update any forward-looking statements, other than as required by law..

除法律规定外，本公司不承诺更新任何前瞻性声明。。

Logo - https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

标志-https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

SOURCE Innocan Pharma Corporation

来源Innocan Pharma Corporation